SCHEMBL2964171

SCHEMBL2964171

CCCc1ccc2c(Nc3cc(OCc4ccc(Cl)cc4)ccc3Sc3ccc(O)cc3)ccnc2n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 1/20 0.45
AKT2 P31751 1/20 0.45
LMNA P02545 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
KDM4E B2RXH2 1/20 0.37
TP53 P04637 1/20 0.37
HTT P42858 1/20 0.37
MAOA P21397 7/20 0.36
MAOB P27338 7/20 0.36
ACHE P22303 1/20 0.36
GAA P10253 1/20 0.34
MAPT P10636 1/20 0.34
ATM Q13315 1/20 0.34
BCAT2 O15382 2/20 0.34
ADORA3 P0DMS8 3/20 0.33
ADORA1 P30542 1/20 0.33
SLC26A4 O43511 1/20 0.32
KMT2A Q03164 1/20 0.32
MAPKAPK2 P49137 1/20 0.32
SREBF2 Q12772 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2965288 0.92 PIM1 (0.49) PIM1AKT2LMNAKDM4EMAOA
SCHEMBL2962127 0.92 PIM1 (0.50) PIM1AKT2LMNAKDM4EMAOA
SCHEMBL2960452 0.91 PIM1 (0.45) PIM1AKT2MAOAMAOBACHE
SCHEMBL2969828 0.89 PIM1 (0.55) PIM1AKT2LMNASMN1; SMN2KDM4E
SCHEMBL2962785 0.87 PIM1 (0.45) PIM1AKT2LMNASMN1; SMN2SREBF2
SCHEMBL2970350 0.86 PIM1 (0.45) PIM1AKT2MAOAMAOBACHE
SCHEMBL2961388 0.86 PIM1 (0.49) PIM1AKT2MAOAMAOB
SCHEMBL2968807 0.85 PIM1 (0.42) PIM1AKT2LMNASMN1; SMN2KDM4E
SCHEMBL2962053 0.83 PIM1 (0.41) PIM1AKT2LMNASMN1; SMN2KDM4E
SCHEMBL2961869 0.82 PIM1 (0.42) PIM1AKT2LMNASMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338605-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2012-12-25 US disclosed
US-20100256139-A1 Anti-Viral Compounds ABBOTT LABORATORIES (US) 2010-10-07 US disclosed
EP-1979349-B1 ANTI-VIRAL COMPOUNDS ABBOTT LAB (US) 2010-07-28 EP disclosed
US-7763731-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2010-07-27 US disclosed
EP-1979349-A2 ANTI-VIRAL COMPOUNDS Abbott Laboratories (US) 2008-10-15 EP disclosed
US-20070232645-A1 ANTI-VIRAL COMPOUNDS ABBVIE INC. 2007-10-04 US disclosed
WO-2007076035-A2 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2007-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232645-A1 ANTI-VIRAL COMPOUNDS HAVCR2, MAVS, EIF2AK2 PIM1 2963/4885AKT2 3903/4885LMNA 3252/4885
US-20100256139-A1 Anti-Viral Compounds HAVCR2, MAVS, EIF2AK2 PIM1 2963/4885AKT2 3903/4885LMNA 3252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.